Inspire Medical Systems, Inc. Announces New Brand Identity and Website to Better Reach Prospective Patients Struggling with Sleep Apnea

Download as PDF

MINNEAPOLIS, MN – August 13, 2019 – Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a
medical technology company focused on the development and commercialization of innovative
and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), recently
revealed its new brand identity and launched a new website.

“While our name and focus on patient outcomes remain the same, our brand identity and
website, InspireSleep.com, have evolved to ensure prospective patients can easily learn about
our innovative sleep apnea treatment,” said Tim Herbert, President and Chief Executive Officer
of Inspire Medical Systems. “Our updated website improves patient education by encouraging
website visitors to learn more about Inspire therapy and connect with an Inspire trained
medical professional.”

“Our focus is on building meaningful and emotional connections. When people struggling with
CPAP visit our website, they will find answers to their questions and be able to connect with a
medical professional to learn more about our innovative treatment option,” said Martin
Abrams, Vice President of Marketing and Customer Experience.

A new advertising campaign called, “A Button”, also launched in conjunction with the new
website. This campaign, which will feature TV, radio, social, and digital ads, shows how simple it
is to get relief from sleep apnea with just the click of a remote.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s
proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that
provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements other than statements of historical
facts are forward-looking statements. In some cases, you can identify forward-looking
statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’
“future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’
‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar
expressions, although not all forward-looking statements contain these words.

These forward-looking statements are based on management’s current expectations and
involve known and unknown risks and uncertainties that may cause our actual results,
performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements. Such risks and
uncertainties include, among others, estimates regarding the annual total addressable market
for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of
operations, financial position, research and development costs, capital requirements and our
needs for additional financing; commercial success and market acceptance of our Inspire
therapy; our ability to achieve and maintain adequate levels of coverage or reimbursement for
our Inspire system or any future products we may seek to commercialize; competitive
companies and technologies in our industry; our ability to enhance our Inspire system, expand
our indications and develop and commercialize additional products; our business model and
strategic plans for our products, technologies and business, including our implementation
thereof; our ability to accurately forecast customer demand for our Inspire system and manage
our inventory; our dependence on third-party suppliers, contract manufacturers and shipping
carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain
our direct sales and marketing organization, and to market and sell our Inspire system in
markets outside of the U.S.; risks associated with international operations; our ability to
manage our growth; our ability to increase the number of active medical centers implanting
Inspire therapy; our ability to hire and retain our senior management and other highly qualified
personnel; risk of product liability claims; risks related to information technology and
cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or
obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in
commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory
actions affecting us or the healthcare industry generally, including healthcare reform measures
in the U.S. and international markets; the timing or likelihood of regulatory filings and
approvals; risks related to our debt and capital structure; our ability to establish and maintain
intellectual property protection for our Inspire therapy and system or avoid claims of
infringement; tax risks; risks that we may be deemed an investment company under the
Investment Company Act of 1940; regulatory risks; the volatility of the trading price of our
common stock; and our expectations about market trends. Other important factors that could
cause actual results, performance or achievements to differ materially from those
contemplated in this press release can be found under the captions “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of Operations“ in our
Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as such factors may
be updated from time to time in our other filings with the SEC, which are accessible on the
SEC’s website at www.sec.gov. These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management’s estimates as of the
date of this press release. While we may elect to update such forward-looking statements at
some point in the future, unless required by applicable law, we disclaim any obligation to do so,
even if subsequent events cause our views to change. Thus, one should not assume that our
silence over time means that actual events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this press release.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com